Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells

Tsang Pai Liu, Pei-Ming Yang

Research output: Contribution to journalArticle

Abstract

Enhancer of zeste homolog 2 (EZH2) is an epigenetic enzyme that mediates gene silencing through tri-methylation of histone H3 lysine 27 (H3K27-me3). Because overexpression of EZH2 in tumors is frequently found, its inhibition has been viewed as a novel anticancer strategy. Numerous small-molecule EZH2 inhibitors have been developed in recent years. S-adenosyl-L-homocysteine (SAH) hydrolase inhibitor, such as 3-Deazaneplanocin A (DZNep), and S-adenosyl-L-methionine (SAM)-competitive inhibitor, such as GSK343, represent two major types of EZH2 inhibitors. DZNep depletes EZH2 protein through the proteasome-dependent pathway. GSK343 directly inhibits the enzyme activity through competing the co-factor SAM. Our results demonstrate that GSK343, but not DZNep, induces apoptosis and autophagic cell death and enhances drug sensitivity in cancer cells. Our study shows, for the first time, that SAM-competitive EZH2 inhibitors are potent autophagy inducers, representing a novel anticancer mechanism for EZH2 inhibitors. Although autophagy is generally seen as a cytoplasmic event, recent studies reveal a transcriptional and epigenetic network that regulates autophagy. In our study, EZH2 seems not to be sufficient to initiate autophagy. However, our results provide some clues that support the promoting role of EZH2 in autophagy, which will be discussed in the highlight.
Original languageEnglish
Pages (from-to)e551-e551
JournalCancer Cell & Microenvironment
Volume2
Publication statusPublished - 2015

Fingerprint

S-Adenosylmethionine
Autophagy
Neoplasms
Epigenomics
Enhancer of Zeste Homolog 2 Protein
Gene Regulatory Networks
Gene Silencing
Homocysteine
Hydrolases
Proteasome Endopeptidase Complex
Enzymes
Histones
Methylation
Lysine
Apoptosis

Cite this

Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells. / Liu, Tsang Pai; Yang, Pei-Ming.

In: Cancer Cell & Microenvironment, Vol. 2, 2015, p. e551-e551.

Research output: Contribution to journalArticle

@article{057bfed0dd264f698907fa1965a67c7f,
title = "Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells",
abstract = "Enhancer of zeste homolog 2 (EZH2) is an epigenetic enzyme that mediates gene silencing through tri-methylation of histone H3 lysine 27 (H3K27-me3). Because overexpression of EZH2 in tumors is frequently found, its inhibition has been viewed as a novel anticancer strategy. Numerous small-molecule EZH2 inhibitors have been developed in recent years. S-adenosyl-L-homocysteine (SAH) hydrolase inhibitor, such as 3-Deazaneplanocin A (DZNep), and S-adenosyl-L-methionine (SAM)-competitive inhibitor, such as GSK343, represent two major types of EZH2 inhibitors. DZNep depletes EZH2 protein through the proteasome-dependent pathway. GSK343 directly inhibits the enzyme activity through competing the co-factor SAM. Our results demonstrate that GSK343, but not DZNep, induces apoptosis and autophagic cell death and enhances drug sensitivity in cancer cells. Our study shows, for the first time, that SAM-competitive EZH2 inhibitors are potent autophagy inducers, representing a novel anticancer mechanism for EZH2 inhibitors. Although autophagy is generally seen as a cytoplasmic event, recent studies reveal a transcriptional and epigenetic network that regulates autophagy. In our study, EZH2 seems not to be sufficient to initiate autophagy. However, our results provide some clues that support the promoting role of EZH2 in autophagy, which will be discussed in the highlight.",
author = "Liu, {Tsang Pai} and Pei-Ming Yang",
year = "2015",
language = "English",
volume = "2",
pages = "e551--e551",
journal = "Cancer Cell & Microenvironment",
issn = "2331-0928",

}

TY - JOUR

T1 - Autophagic effect of SAM-competitive EZH2 inhibitors on cancer cells

AU - Liu, Tsang Pai

AU - Yang, Pei-Ming

PY - 2015

Y1 - 2015

N2 - Enhancer of zeste homolog 2 (EZH2) is an epigenetic enzyme that mediates gene silencing through tri-methylation of histone H3 lysine 27 (H3K27-me3). Because overexpression of EZH2 in tumors is frequently found, its inhibition has been viewed as a novel anticancer strategy. Numerous small-molecule EZH2 inhibitors have been developed in recent years. S-adenosyl-L-homocysteine (SAH) hydrolase inhibitor, such as 3-Deazaneplanocin A (DZNep), and S-adenosyl-L-methionine (SAM)-competitive inhibitor, such as GSK343, represent two major types of EZH2 inhibitors. DZNep depletes EZH2 protein through the proteasome-dependent pathway. GSK343 directly inhibits the enzyme activity through competing the co-factor SAM. Our results demonstrate that GSK343, but not DZNep, induces apoptosis and autophagic cell death and enhances drug sensitivity in cancer cells. Our study shows, for the first time, that SAM-competitive EZH2 inhibitors are potent autophagy inducers, representing a novel anticancer mechanism for EZH2 inhibitors. Although autophagy is generally seen as a cytoplasmic event, recent studies reveal a transcriptional and epigenetic network that regulates autophagy. In our study, EZH2 seems not to be sufficient to initiate autophagy. However, our results provide some clues that support the promoting role of EZH2 in autophagy, which will be discussed in the highlight.

AB - Enhancer of zeste homolog 2 (EZH2) is an epigenetic enzyme that mediates gene silencing through tri-methylation of histone H3 lysine 27 (H3K27-me3). Because overexpression of EZH2 in tumors is frequently found, its inhibition has been viewed as a novel anticancer strategy. Numerous small-molecule EZH2 inhibitors have been developed in recent years. S-adenosyl-L-homocysteine (SAH) hydrolase inhibitor, such as 3-Deazaneplanocin A (DZNep), and S-adenosyl-L-methionine (SAM)-competitive inhibitor, such as GSK343, represent two major types of EZH2 inhibitors. DZNep depletes EZH2 protein through the proteasome-dependent pathway. GSK343 directly inhibits the enzyme activity through competing the co-factor SAM. Our results demonstrate that GSK343, but not DZNep, induces apoptosis and autophagic cell death and enhances drug sensitivity in cancer cells. Our study shows, for the first time, that SAM-competitive EZH2 inhibitors are potent autophagy inducers, representing a novel anticancer mechanism for EZH2 inhibitors. Although autophagy is generally seen as a cytoplasmic event, recent studies reveal a transcriptional and epigenetic network that regulates autophagy. In our study, EZH2 seems not to be sufficient to initiate autophagy. However, our results provide some clues that support the promoting role of EZH2 in autophagy, which will be discussed in the highlight.

UR - http://smartscitech.com/index.php/CCM/article/view/551

M3 - Article

VL - 2

SP - e551-e551

JO - Cancer Cell & Microenvironment

JF - Cancer Cell & Microenvironment

SN - 2331-0928

ER -